In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

AstraZeneca (AZ), GlaxoSmithKline (GSK) and Johnson & Johnson Innovation have unveiled a new collaboration with three of the UK's top universities to help accelerate groundbreaking academic ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

AstraZeneca's Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in eosinophilic granulomatosis with ...

Though prescribing climate-friendly inhalers is environmentally sound, some experts warn certain patients may be overlooked.

AstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been hit by disruption caused by the COVID-19 pandemic.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Astrazeneca is set to report earnings next week after a turbulant few months for the FTSE 100 firm and its China arm.

AMGN/AstraZeneca’s tezepelumab, and GSK’s mepolizumab are in development, promising more options to transform COPD management ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Dominic Walsh, a business reporter who previously covered the leisure and drinks industry for The Times from 1997 to 2024, stated in post to X: ...

CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS is expected to come in at $2.04 in the third quarter, according to a company-compiled consensus ...